Revenue
257 thousand CAD
2019 · CAD
Exact inputs and evidence
- Revenue: 257099 CAD Source
Fundies. English
Quantum Biopharma Ltd.
EDGAR305 filing records in this dataset, filed from 2020-01-09 to 2026-10-08. Reported financial figures are available; chart coverage varies by period.
Latest fiscal year
- Cash and cash equivalents
- 3.65 million USD Source
Exact value
3647072 USD
- Long-term debt including current maturities
- Not available
- Shares outstanding
- Not available
Trailing twelve months
The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.
Operating cash flow
-5.49 million USD
2025-07-01 – 2026-06-30
Exact inputs and evidence
- Operating cash flow: -7931414 USD · 2025-01-01 – 2025-09-30 Source
- Operating cash flow: -6209938 USD · 2025-01-01 – 2025-06-30 Source
- Operating cash flow: -8237012 USD · 2025-01-01 – 2025-12-31 Source
- Operating cash flow: -7931414 USD · 2025-01-01 – 2025-09-30 Source
- Operating cash flow: -1668749 USD · 2026-01-01 – 2026-03-31 Source
- Operating cash flow: -3458471 USD · 2026-01-01 – 2026-06-30 Source
- Operating cash flow: -1668749 USD · 2026-01-01 – 2026-03-31 Source
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-10-08.
Financial data available through: 2025-12-31.
Coverage by financial measure
- Revenue: 1 of 11 periods available· newest 2019-12-31
- Operating income: 7 of 11 periods available· newest 2025-12-31
- net income: No compatible figures in this window
- Operating cash flow: 7 of 11 periods available· newest 2025-12-31
- Capital expenditure: 5 of 11 periods available· newest 2024-12-31
- Total assets: 8 of 11 periods available· newest 2025-12-31
- Total liabilities: 8 of 11 periods available· newest 2025-12-31
- Current assets: 8 of 11 periods available· newest 2025-12-31
- Current liabilities: 8 of 11 periods available· newest 2025-12-31
- Cash and cash equivalents: 8 of 11 periods available· newest 2025-12-31
- long term debt: No compatible figures in this window
- shares outstanding: No compatible figures in this window
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Operating cash flow
−USD 1.36 millionPrior period
−USD 6.88 million
–
Current period
−USD 8.24 million
–
Exact inputs and evidence
-8237012 − -6876479 = -1360533 USD
-6876479 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-8237012 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Revenue, Net income, Capital expenditure.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
2019 2019-01-01 – 2019-12-31
- Revenue CAD 257,099 100% of revenue
- Operating costs Derived Unavailable An input is unavailable.
- Operating income Unavailable An input is unavailable.
- Tax, interest and other Derived Unavailable An input is unavailable.
- Net income Unavailable An input is unavailable.
Cash
- Operating cash flow Unavailable An input is unavailable.
- Capital expenditure Unavailable An input is unavailable.
- Free cash flow Derived Unavailable An input is unavailable.
Share of revenue by period
- Net income
- Tax, interest and other
- Operating costs
- 2019 Not shown: operating income or net income is not reported.
Values and sources
| Period | Revenue | Operating costs | Operating income | Tax, interest and other | Net income | Free cash flow | Source |
|---|---|---|---|---|---|---|---|
| 2019 2019-01-01 – 2019-12-31 | 257099 | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Source
|
Amounts are exact, in CAD.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
CAD 257.1K 2019
Values and sources
| Period | Series | Value(CAD) | Source evidence |
|---|---|---|---|
| 2019 | Revenue | 257099 |
|
Revenue growth
Change in revenue from the same financial period one year earlier.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2019 | Year over year | No prior comparable period |
|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Not enough comparable data to show this history.
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2019-12-31 | Operating margin | Not reported |
|
| 2019-12-31 | Net margin | Not reported |
|
| 2019 | Free cash flow margin | Not reported |
|
Operating cash flow
Cash generated by the company’s normal business operations.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value(CAD) | Source evidence |
|---|---|---|---|
| 2019 | Operating cash flow | Not reported | No source recorded |
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2019 | Free cash flow | Unavailable | No source recorded |
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2019-12-31 | Liabilities / assets | Not reported | No source recorded |
Current assets to current liabilities
Current assets divided by current liabilities.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2019-12-31 | Current assets / current liabilities | Not reported | No source recorded |
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2019 2019-01-01 – 2019-12-31 | Unavailable Not reported for this period. | −USD 13.71 million Exact valueExact value: -13712725 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2019 2019-01-02 – 2019-12-31 | Unavailable Not reported for this period. | −USD 13.71 million Exact valueExact value: -13712725 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2020 2020-01-01 – 2020-12-31 | Unavailable Not reported for this period. | −USD 19.13 million Exact valueExact value: -19130473 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 0 Exact valueExact value: 0 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 19.13 million Calculation and evidence-19130473 − 0 USD Exact free cash flow: -19130473 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2021 2021-01-01 – 2021-12-31 | Unavailable Not reported for this period. | −USD 20.75 million Exact valueExact value: -20746223 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 0 Exact valueExact value: 0 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 20.75 million Calculation and evidence-20746223 − 0 USD Exact free cash flow: -20746223 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2022 2022-01-01 – 2022-12-31 | Unavailable Not reported for this period. | −USD 28.33 million Exact valueExact value: -28333273 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 113,958 Exact valueExact value: 113958 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 28.45 million Calculation and evidence-28333273 − 113958 USD Exact free cash flow: -28447231 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2023 2023-01-01 – 2023-12-31 | Unavailable Not reported for this period. | −USD 10.83 million Exact valueExact value: -10827264 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 0 Exact valueExact value: 0 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 10.83 million Calculation and evidence-10827264 − 0 USD Exact free cash flow: -10827264 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2024 2024-01-01 – 2024-12-31 | Unavailable Not reported for this period. | −USD 6.88 million Exact valueExact value: -6876479 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 0 Exact valueExact value: 0 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 6.88 million Calculation and evidence-6876479 − 0 USD Exact free cash flow: -6876479 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2025 2025-01-01 – 2025-12-31 | Unavailable Not reported for this period. | −USD 8.24 million Exact valueExact value: -8237012 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
305 filings · 786 latest values · 786 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001771885, 1771885, HUGE, QNTM, edgar:1771885
Also known as FSD Pharma Inc., QUANTUM BIOPHARMA LTD., Quantum BioPharma Ltd., Quantum Biopharma Ltd.